That keeps things interesting.
In a previous post, I was able to show how sequence quality values could be used to summarize the data for a large resequencing assay. Presenting "per read" quality values in a grid format allowed us to visualize samples that had failed as well as observe that some amplicons contained repeats that led to sequencing artifacts. We also were able to identify potential sample tracking issues and left off with an assignment to think about how we might further test sample tracking in the assay.
When an assay is developed there are often certain results that can be expected. Some results are defined explicitly with positive and negative controls. We can also use assay results to test that the assay is producing the right kinds of information. Do the data make sense? Expectations can be derived from the literature, an understanding of statistical outcomes, or internal measures.
Genetic assays have common parts
A typical genetic resequencing assay is developed from known information. The goal is to collect sequences from a defined region of DNA for a population of individuals (samples) and use the resulting data to observe the frequency of known differences (variants) and identify new patterns of variation. Each assay has three common parts:
Gene Model - Resequencing and genotyping projects involve comparative analysis of new data (sequences, genotypes) to reference data. The Gene Model can be a chromosomal region or specific gene. A well-developed model will include all known genotypes, protein variations, and phenotypes. The Gene Model represents both community (global) and laboratory (local) knowledge.
Assay Design - The Assay Design defines the regions in the Gene Model that will be analyzed. These regions, typically prepared by PCR are bounded by unique DNA primer sequences. The PCR primers have two parts: one part is complementary to the reference sequence (black in the figure), the other part is "universal" and is complementary to a sequencing primer (red in the figure). The study includes information about patient samples such as their ethnicity, collection origin, and phenotypes associated with the gene(s) under study.
Experiments / Data Collection / Analysis - Once the study is designed and materials arrive, samples are prepared for analysis. PCR is used to amplify specific regions for sequencing or genotyping. After a scientist is confident that materials will yield results, data collection begins. Data can be collected in the lab or the lab can outsource their sequencing to core labs or service companies. When data are obtained, they are processed, validated, and compared to reference data.
Setting expectations
A major challenge for scientists doing resequencing and genotyping projects arises when trying to evaluate data quality and determine the “next steps.” Rarely does everything work. We've already talked about read quality, but there are also the questions of whether the data are mapping to their expected locations, and whether the frequencies of observed variation are expected. The Assay Design can be used to verify experimental data.
The Assay Design tells us where the data should align and how much variation can be expected. For example, if the average SNP frequency is 1/1300 bases, and an average amplicon length is 580 bases, we should expect to observe one SNP for every two amplicons. Furthermore, in reads where a SNP may be observed, we will see the difference in a subset of the data because some, or most, of the reads will have the same allele as the reference sequence.
To test our expectations for the assay, the 7488 read data set is summarized in a way that counts the frequency of disagreements between read data and their reference sequence. The graph below shows a composite of read discrepancies (blue bar graph) and average Q20/rL, Q30/rL, Q40/rL values (colored line graphs). Reads are grouped according to the number of discrepancies observed (x-axis). For each group, the count of reads (bar height) and average Q20/rL (green triangles), Q30/rL (yellow squares), and Q40/rL (purple circles) are displayed.
In the 7488 read data set, 95% (6914) of the reads gave alignments. Of the aligned data, 82% of the reads had between 0 and 4 discrepancies. If we were to pick which traces to review and which to samples to redo, we would likely focus our review on the data in this group and queue the rest (18%) for redos to see if we could improve the data quality.
Per our previous prediction, most of the data (5692 reads) do not have any discrepancies. We also observe that the number of discrepancies increases as the overall data quality decreases. This is expected because the quality values are reflecting the uncertainty (error) in the data.
Per our previous prediction, most of the data (5692 reads) do not have any discrepancies. We also observe that the number of discrepancies increases as the overall data quality decreases. This is expected because the quality values are reflecting the uncertainty (error) in the data.
Spotting tracking issues
We can also use our expectations to identify sample tracking issues. Once an assay is defined, the positions of all of the PCR primers are known, hence we should expect that our sequence data will align to the reference sequence in known positions. In our data set, this is mostly true. Similar to the previous quality plots of samples and amplicons, an alignment "quality" can be defined and displayed in a table where the rows are samples and columns are amplicons. Each sample has two rows (one forward and one reverse sequence). If the cells are colored according to alignment start positions (green for expected, red for unexpected, white for no alignment) we can easily spot which reads have an "unexpected" alignment. The question then becomes, where/when did the mixup occur?
From these kinds of analyses we can get a feel for whether a project is on track and whether there are major issues that will make our lives harder. In future posts I will comment on other kinds of measures that can be made and show you how this work can be automated in FinchLab.
No comments:
Post a Comment